Tempus AI (NASDAQ:TEM) CEO Sells 250,000 Shares of Company Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 250,000 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the sale, the chief executive officer directly owned 100,000 shares of the company’s stock, valued at approximately $7,747,000. The trade was a 71.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Up 7.4%

TEM stock traded up $5.65 during trading on Thursday, reaching $82.24. The stock had a trading volume of 10,773,536 shares, compared to its average volume of 6,157,478. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm has a fifty day moving average price of $58.39 and a 200 day moving average price of $53.43. The company has a market capitalization of $14.84 billion, a P/E ratio of -57.11 and a beta of 3.72. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same period last year, the firm earned ($0.22) earnings per share. The company’s revenue was up 21.6% on a year-over-year basis. On average, equities analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. UBS Group began coverage on Tempus AI in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 target price on the stock. BTIG Research raised their price target on shares of Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. HC Wainwright lifted their price target on shares of Tempus AI from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. Raymond James Financial set a $80.00 price target on shares of Tempus AI in a report on Wednesday, September 2nd. Finally, Freedom Capital raised shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Eleven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $69.63.

Institutional Investors Weigh In On Tempus AI

Several institutional investors and hedge funds have recently made changes to their positions in the company. EMC Capital Management bought a new stake in Tempus AI during the second quarter valued at $29,000. Whittier Trust Co. lifted its position in shares of Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after buying an additional 570 shares during the last quarter. CoreCap Advisors LLC boosted its holdings in shares of Tempus AI by 293.4% in the 2nd quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after buying an additional 760 shares during the period. Global Assets Advisory LLC bought a new stake in shares of Tempus AI during the 1st quarter valued at about $46,000. Finally, Eurizon Capital SGR S.p.A. bought a new stake in shares of Tempus AI during the 4th quarter valued at about $70,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.